Ozempic’s monthly cost significantly decreases following the Trump deal
Following President Donald Trump’s announcement of a deal with pharmaceutical companies to lower the cost of two well-known medications in the US. Novo Nordisk lowered the direct-to-consumer costs of its weight-loss medication Wegovy and diabetes treatment Ozempic on Monday, challenging Eli Lilly’s Zepbound.
Novo Nordisk made an offer for new cash-paying customers to buy the two lowest dosages of either medication for $199 per month for the first two months. The monthly cost of Ozempic and Wegovy, which patients must pay out of pocket, has decreased from $499 to $349.
Earlier this month, Trump, who advocated for lower prescription prices in the US, announced a deal with Novo Nordisk and Eli Lilly. That would enable Medicare and Medicaid beneficiaries to buy weight-loss medications at a reduced rate on a brand-new website named «TrumpRx.»
According to a statement from Novo Nordisk’s executive vice president of US operations, Dave Moore, the company aims to make its medications «affordable and accessible to those who need them.»
Ozempic and Wegovy are less expensive than Eli Lilly’s Zepbound, which costs $349 per month for the lowest dosage.
According to Novo Nordisk, the monthly out-of-pocket expense for the maximum dosage of Ozempic—a 2-milligram injection—would stay at $499.
Eli Lilly’s stock fell 0.2%, however Novo Nordisk’s stock was unaffected by the announcement.
